Probenecid
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB01032 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 45 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | hypouricemia, renal | KG + DL |
| 2 | Lesch-Nyhan syndrome | KG + DL |
| 3 | hypoxanthine guanine phosphoribosyltransferase partial deficiency | KG + DL |
| 4 | cholelithiasis | KG + DL |
| 5 | primitive portal vein thrombosis | KG + DL |
| 6 | hepatoportal sclerosis | KG + DL |
| 7 | hepatopulmonary syndrome | KG + DL |
| 8 | idiopathic copper-associated cirrhosis | KG + DL |
| 9 | early-onset familial noncirrhotic portal hypertension | KG + DL |
| 10 | disorder of phenylalanine metabolism | KG + DL |
| 11 | hepatic porphyria | KG + DL |
| 12 | genetic otorhinolaryngological malformation | KG + DL |
| 13 | neonatal epileptic encephalopathy due to glutaminase deficiency | KG + DL |
| 14 | semicircular canal dehiscence syndrome | KG + DL |
| 15 | idiopathic bilateral vestibulopathy | KG + DL |
| 16 | juvenile nasopharyngeal angiofibroma (disease) | KG + DL |
| 17 | familial nasal acilia | KG + DL |
| 18 | silent sinus syndrome | KG + DL |
| 19 | inborn disorder of phenylalanin or tyrosine metabolism | KG + DL |
| 20 | tetrahydrobiopterin metabolic process disease | KG + DL |
| 21 | maternal hyperthermia induced birth defects | KG + DL |
| 22 | disorder of tyrosine metabolism | KG + DL |
| 23 | cleft lip/palate-intestinal malrotation-cardiopathy syndrome | KG + DL |
| 24 | craniorhiny | KG + DL |
| 25 | fetal minoxidil syndrome | KG + DL |
| 26 | phenobarbital embryopathy | KG + DL |
| 27 | brain small vessel disease 1 with or without ocular anomalies | KG + DL |
| 28 | fetal trimethadione syndrome | KG + DL |
| 29 | Bencze syndrome | KG + DL |
| 30 | branchial cleft anomaly | KG + DL |
| 31 | velo-facial-skeletal syndrome | KG + DL |
| 32 | mandibulofacial dysostosis-macroblepharon-macrostomia syndrome | KG + DL |
| 33 | phenylketonuria | KG + DL |
| 34 | diabetic embryopathy | KG + DL |
| 35 | autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome | KG + DL |
| 36 | teratogenic Pierre Robin syndrome | KG + DL |
| 37 | hereditary renal hypouricemia | KG + DL |
| 38 | propylthiouracil embryofetopathy | KG + DL |
| 39 | indomethacin embryofetopathy | KG + DL |
| 40 | glycogen storage disease due to hepatic glycogen synthase deficiency | KG + DL |
| 41 | tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria | KG + DL |
| 42 | cocaine embryofetopathy | KG + DL |
| 43 | tibial aplasia-ectrodactyly syndrome | KG + DL |
| 44 | aminopterin/methotrexate embryofetopathy | KG + DL |
| 45 | toluene embryopathy | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.